MedPath

ONGLYZA

These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA. ONGLYZA (saxagliptin) tablets Initial U.S. Approval: 2009

Approved
Approval ID

d45fc842-2563-4421-86af-a55b3191e19b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 9, 2012

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

SAXAGLIPTIN

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54868-6309
Application NumberNDA022350
Product Classification
M
Marketing Category
C73594
G
Generic Name
SAXAGLIPTIN
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 9, 2012
FDA Product Classification

INGREDIENTS (5)

lactose monohydrateInactive
Code: EWQ57Q8I5X
Classification: IACT
cellulose, microcrystallineInactive
Code: OP1R32D61U
Classification: IACT
croscarmellose sodiumInactive
Code: M28OL1HH48
Classification: IACT
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT
saxagliptin hydrochlorideActive
Quantity: 5 mg in 1 1
Code: Z8J84YIX6L
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ONGLYZA - FDA Drug Approval Details